The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
161
1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Arizona Advanced Eye Research Institute
Glendale, Arizona, United States
Mean Diurnal IOP
IOP measurement with calibrated Goldmann applanation tonometer in each eye at three time points (8:00 AM; 10:00 AM; 4:00 PM) by the Investigator. Mean diurnal is calculated from these three timepoints.
Time frame: The primary efficacy endpoint is the change from baseline (D1) at Week 7 in the mean diurnal IOP in the study eye.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Global Research Management, Inc.
Glendale, California, United States
United Medical Research Institute
Inglewood, California, United States
Eye Research Foundation
Newport Beach, California, United States
Visionary Research Institute
Newport Beach, California, United States
North Bay Eye Associates
Petaluma, California, United States
Sacramento Eye Consultants, A Medical Corporation
Sacramento, California, United States
Wolstan and Goldberg Eye Associates
Torrance, California, United States
Segal Drug Trials, Inc
Delray Beach, Florida, United States
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
...and 14 more locations